Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Gynecology · Ovarian Dermoid Cyst

Pathology & Risk of Malignancy

At a Glance

Most ovarian dermoid cysts, also called mature cystic teratomas, are benign. Malignant transformation is rare, but older age, menopause, large size, or rapid growth can raise concern; only microscopic examination of tissue after surgery can confirm the diagnosis.

Finding a mass in your ovary often leads to an immediate fear of cancer. While it is important to be thorough, it is equally important to know that the vast majority of ovarian dermoid cysts (mature cystic teratomas) are entirely benign [1]. In a very small number of cases, a specific type of cancer can develop within the cyst—a process known as malignant transformation [2].

Understanding the Risk

Malignant transformation is rare. Most large medical studies estimate that it occurs in only about 0.2% to 2% of all ovarian dermoid cysts [3][4].

This transformation typically happens when one of the mature tissues already inside the cyst—most often the skin-like lining—turns into cancer [2]. Because it usually starts in the skin tissue, the most common type of cancer found is squamous cell carcinoma (SCC) [5].

Who is at higher risk?

While anyone with a dermoid cyst should have it evaluated, certain factors are associated with a higher likelihood of transformation. These are risk associations, not predictions for any one person:

  • Age: Transformation is most common in patients who are postmenopausal or over the age of 45 [6][7].
  • Tumor Size: Cysts that are larger than 10 cm (about the size of a grapefruit) or as large as 15 cm are more likely to contain a malignant area than smaller cysts [6][8].
  • Rapid Growth: If a cyst that was stable for years suddenly begins to grow quickly, it may warrant closer investigation [9].

The Truth About Tumor Markers

Before surgery, your doctor may order blood tests called tumor markers. It is vital to understand that these tests are not “cancer tests”—they are pieces of a larger puzzle.

  • CA 19-9: This marker is very commonly elevated in patients with benign dermoid cysts [10]. A high number here can be startling, but it often simply reflects the activity of the cyst itself and usually drops back to normal once the cyst is removed [10][11].
  • CA-125: This is a general marker for ovarian irritation. While it can be elevated in cancer, it is also frequently elevated due to benign conditions like endometriosis or simple cyst inflammation [6][12].
  • SCC Antigen: If a doctor strongly suspects a dermoid has transformed into squamous cell carcinoma, they may check this specific marker, but it is not a routine definitive test [13][14].

Because these markers can be “false positives,” doctors never use them alone to make a diagnosis [15]. A normal marker does not exclude malignant transformation and an elevated marker does not diagnose it. They are interpreted alongside your age, symptoms, and imaging results [16].

Interpreting Your Pathology Report

The only way to definitively know if a cyst is benign is through a histopathological examination—where a pathologist looks at the tissue under a microscope after surgery [17]. You should review the signed pathology diagnosis directly with your clinician.

When you receive your final pathology report, here are the key terms to look for:

  • “Mature Tissue”: This is the expected finding in a mature teratoma. It means the tissues inside (like skin, fat, or hair) are fully developed [1].
  • “No Atypia” or “No Malignancy”: This confirms that the sampled cells do not show signs of cancer [2].
  • “Squamous Cell Carcinoma”: If this is mentioned, it means a malignant transformation was found [18][19].
  • “Immature Elements”: If these are present, the diagnosis might change from a “mature” teratoma to an immature teratoma, which is a different type of germ cell tumor [20].

If squamous cell carcinoma, invasion, immature elements, or atypia are found, these require prompt review with the gynecologic team and often a referral to a gynecologic oncologist for specific management. If your report confirms a mature cystic teratoma with no unusual features, you can feel confident that the mass was benign [1].

Common questions in this guide

How common is cancer in an ovarian dermoid cyst?
Most ovarian dermoid cysts, also called mature cystic teratomas, are benign. Malignant transformation is rare, occurring in about 0.2% to 2% of cases. Older age, postmenopausal status, a large cyst, or rapid growth may raise concern but do not predict cancer in any one person.
Does a high CA 19-9 mean that my dermoid cyst is cancerous?
No. CA 19-9 is often elevated in benign ovarian dermoid cysts, and CA-125 can also rise with noncancerous irritation or inflammation. These blood tests must be interpreted with imaging and clinical information and cannot diagnose or exclude malignant transformation by themselves.
What do mature tissue and no atypia mean on a dermoid cyst pathology report?
Mature tissue means the cyst contains fully developed tissues such as skin, fat, or hair, which is expected in a mature cystic teratoma. No atypia or no malignancy means the examined cells do not show the abnormal features of cancer. Together, these findings are generally reassuring when the report confirms a mature cystic teratoma.
What does squamous cell carcinoma or invasion mean in a dermoid cyst?
Squamous cell carcinoma in an ovarian dermoid cyst means that the skin-like tissue inside the cyst has become cancerous. The pathology report should clarify whether the cancer is confined to the cyst or has invaded surrounding tissue. These findings need prompt review with a gynecologic team, often including a gynecologic oncologist.
Can an ultrasound, MRI, or blood test confirm malignant transformation?
Ultrasound or MRI may show features that need closer evaluation, such as vascularized solid components or mural nodules, and tumor markers can provide supporting information. None of these tests can confirm malignant transformation on its own. A pathologist examining tissue after surgery provides the definitive diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my age and the size of the cyst, how would you characterize my statistical risk for malignant transformation?
  2. 2.Did my ultrasound or MRI show any 'vascularized solid components' or 'mural nodules' that might be more concerning than typical fat and hair?
  3. 3.My CA 19-9 level is elevated—could this be a result of the benign dermoid cyst itself rather than a sign of cancer?
  4. 4.On the pathology report, does it state that 'mature' tissues were found in all sampled areas?
  5. 5.Were there any 'immature elements' or 'atypia' mentioned in the final report?
  6. 6.If the pathology report mentions 'squamous cell carcinoma,' was it confined to the cyst or was there 'stromal invasion'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Chemical peritonitis resulting from spontaneous rupture of a mature ovarian cystic teratoma: a case report.

    Bužinskienė D, Mongirdas M, Mikėnas S, et al.

    Acta medica Lituanic 2019; (26(4)):217-226 doi:10.6001/actamedica.v26i4.4207.

    PMID: 32355460
  2. 2

    Malignant transformation of mature cystic teratoma of the ovary.

    Atwi D, Kamal M, Quinton M, Hassell LA

    The journal of obstetrics and gynaecology research 2022; (48(12)):3068-3076 doi:10.1111/jog.15409.

    PMID: 36053141
  3. 3

    Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review.

    Li C, Zhang Q, Zhang S, et al.

    BMC cancer 2019; (19(1)):217 doi:10.1186/s12885-019-5393-y.

    PMID: 30866852
  4. 4

    30-Year Experience With 22 Cases of Malignant Transformation Arising From Ovarian Mature Cystic Teratoma: A Rare Disease.

    Li Y, Qin M, Shan Y, et al.

    Frontiers in oncology 2022; (12()):842703 doi:10.3389/fonc.2022.842703.

    PMID: 35615156
  5. 5

    Leiomyosarcoma and Squamous Cell Carcinoma Arising in Mature Cystic Teratoma of the Ovary.

    Pongsuvareeyakul T, Sukpan K, Chaicharoen S, Khunamornpong S

    Case reports in pathology 2017; (2017()):7907359 doi:10.1155/2017/7907359.

    PMID: 28751996
  6. 6

    Risk factors for malignant transformation of mature cystic teratoma.

    Park CH, Jung MH, Ji YI

    Obstetrics & gynecology science 2015; (58(6)):475-80 doi:10.5468/ogs.2015.58.6.475.

    PMID: 26623411
  7. 7

    Malignant transformation in mature cystic teratoma of the ovary: a retrospective study of eight cases and review of literature.

    Rathore R, Sharma S, Agarwal S

    Przeglad menopauzalny = Menopause review 2018; (17(2)):63-68 doi:10.5114/pm.2018.77304.

    PMID: 30150913
  8. 8

    Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study.

    Chiang AJ, Chen MY, Weng CS, et al.

    Journal of gynecologic oncology 2017; (28(5)):e69 doi:10.3802/jgo.2017.28.e69.

    PMID: 28657230
  9. 9

    Rare case of squamous cell carcinoma arising in a recurrent ovarian mature cystic teratoma of a young woman: A case report and review of the literature.

    Feng X, Xu L

    Medicine 2018; (97(20)):e10802 doi:10.1097/MD.0000000000010802.

    PMID: 29768376
  10. 10

    Extreme elevation of CA 19-9 levels in mature cystic teratoma without any complications: A case report.

    Cho A, Kim BR, Lim SH, Park CM

    Annals of medicine and surgery (2012) 2022; (78()):103803 doi:10.1016/j.amsu.2022.103803.

    PMID: 35734746
  11. 11

    Mature Cystic Teratoma of Ovary with Abnormally High Levels of Ca19-9: A Case Report.

    Sampaio J, Sarmento-Gonçalves I, Barros JM, et al.

    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2016; (38(7)):365-7 doi:10.1055/s-0036-1586161.

    PMID: 27434195
  12. 12

    Malignant Transformation in a Mature Cystic Teratoma of the Ovary: A 5-year Descriptive Study.

    Billod JA, Manangan-Wong RM

    Acta medica Philippina 2024; (58(15)):55-60 doi:10.47895/amp.vi0.8023.

    PMID: 39308880
  13. 13

    Advanced squamous cell carcinomas arising from mature cystic teratoma of the ovary: a retrospective case series at the Tohoku Gynecologic Cancer Unit.

    Tokunaga H, Watanabe Y, Kaiho M, et al.

    International cancer conference journal 2016; (5(3)):146-149 doi:10.1007/s13691-016-0246-x.

    PMID: 31149443
  14. 14

    Imaging in gynecological disease (31): clinical and ultrasound characteristics of ovarian mature cystic teratomas containing malignancies.

    Giudice MT, Moro F, Pozzati F, et al.

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2026; (67(6)):852-863 doi:10.1002/uog.70224.

    PMID: 42552511
  15. 15

    Frequency and clinicopathological features of somatic neoplasms arising in ovarian mature teratomas: a single-center experience.

    Yıldırım Ş, Bülbül GA, Nergiz D, et al.

    Pathology oncology research : POR 2026; (32()):1612455 doi:10.3389/pore.2026.1612455.

    PMID: 42500623
  16. 16

    Malignancy Arising in Dermoid Cysts: A Case Report and Literature Review.

    Arab M, Ashtiani AJ, Faghih N, et al.

    Journal of family & reproductive health 2023; (17(4)):264-268 doi:10.18502/jfrh.v17i4.14599.

    PMID: 38807623
  17. 17

    Squamous Cell Carcinoma Arising From Mature Cystic Teratoma in a 39-Year-Old Woman: A Case Report.

    Ananika TA, Koutrouli MR, Vlachos I, et al.

    Cureus 2026; (18(6)):e110609 doi:10.7759/cureus.110609.

    PMID: 42434637
  18. 18

    Squamous Cell Carcinoma Originating From Mature Cystic Teratoma of the Ovary Diagnosed 10 Years After Initial Tumor Detection: A Case Report.

    Ohira S, Kitano R, Yokoi Y, et al.

    Cureus 2024; (16(12)):e76470 doi:10.7759/cureus.76470.

    PMID: 39867042
  19. 19

    Squamous Cell Carcinoma Arising in a Mature Cystic Teratoma of the Ovary Presenting With a Ruptured Sister Mary Joseph Nodule: A Rare Case Report From Northern Tanzania.

    Lugata J, Smith C, Mrosso O, et al.

    Clinical case reports 2026; (14(9)):e73461 doi:10.1002/ccr3.73461.

    PMID: 42688378
  20. 20

    Unusual Variants of Teratoma Involving the Gynecologic Tract.

    Guido LP, Camacho F, Freire R, Pinto A

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2022; (41(4)):320-326 doi:10.1097/PGP.0000000000000813.

    PMID: 34320530

This page explains ovarian dermoid cyst pathology and malignancy risk for informational purposes only and is not medical advice. Your gynecologist, pathologist, or gynecologic oncologist should interpret your results and advise you.

Get notified when new evidence is published on dermoid cyst.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.